Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial.
Publication year
2024Source
Journal of the Pediatric Infectious Diseases Society, 13, 9, (2024), pp. 496-500ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Pharmacy
Journal title
Journal of the Pediatric Infectious Diseases Society
Volume
vol. 13
Issue
iss. 9
Page start
p. 496
Page end
p. 500
Subject
Pharmacy - Radboud University Medical CenterAbstract
We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%-30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.
This item appears in the following Collection(s)
- Academic publications [245350]
- Electronic publications [132838]
- Faculty of Medical Sciences [93207]
- Open Access publications [106383]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.